公开(公告)号：EP2608778A2

公开(公告)日：2013-07-03

申请号：EP11820752.1

申请日：2011-08-26

申请人： University Of Louisville Research Foundation, Inc.

发明人： VOOR, Michael J. ,  BURDEN, JR., Robert L.

IPC分类号： A61K9/16 ,  A61K33/14 ,  A61K33/06 ,  A61K33/00 ,  A61P19/10 ,  A61P19/00

CPC分类号： A61L24/0063 ,  A61F2/28 ,  A61F2002/30166 ,  A61F2002/30199 ,  A61F2310/00359 ,  A61K35/32 ,  A61L24/001 ,  A61L24/0015 ,  A61L24/0042 ,  A61L24/0068 ,  A61L27/3608 ,  A61L27/365 ,  A61L27/425 ,  A61L27/427 ,  A61L27/50 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/406 ,  A61L2300/412 ,  A61L2430/02

摘要： A bone graft composition includes a biologically-resorbable cement and a plurality of processed bone particles, where each of the bone particles have a shape configured to interconnect with adjacent bone particles. A method for treating a bone defect using the bone graft compositions includes providing the bone graft composition and administering an effective amount of the bone graft composition to a site of a bone defect in a subject. Kits including a biologically-resorbable cement powder and a plurality of processed bone particles are also provided.

摘要翻译： 骨移植组合物包括生物可再吸收的水泥和多个加工的骨颗粒，其中每个骨颗粒具有被配置成与相邻的骨颗粒相互连接的形状。 使用骨移植组合物治疗骨缺损的方法包括提供骨移植组合物并将有效量的骨移植组合物施用于受试者的骨缺损部位。 还提供了包括生物可再吸收的水泥粉末和多个加工的骨颗粒的试剂盒。

公开(公告)号：EP2606125A2

公开(公告)日：2013-06-26

申请号：EP11818884.6

申请日：2011-08-22

申请人： Immunovative Therapies, Ltd.

发明人： HAR-NOY, Michael

IPC分类号： C12N5/0783 ,  A61K35/12

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/57 ,  C12N5/0638 ,  C12N2501/51 ,  C12N2501/515

摘要： A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient.

公开(公告)号：EP2591683A3

公开(公告)日：2013-06-19

申请号：EP13153016.4

申请日：2009-05-15

申请人： Bioexx Specialty Proteins Ltd.

发明人： TANG, Nelson

IPC分类号： A23J1/14 ,  A23J3/14 ,  A23J3/30 ,  C07K1/14 ,  C12P21/06 ,  A23J1/00 ,  C07K14/415

CPC分类号： A23J3/14 ,  A23J1/14 ,  A23J3/16 ,  C07K14/415

摘要： Protein concentrates and protein isolates, in addition to processes for the production of protein concentrates and protein isolates, are disclosed. In particular, the disclosure relates to a process for removing fiber from an oilseed meal, comprising: i) mixing an oilseed meal with a blending solvent, optionally water, saline solution, polysaccharide solution or protein containing solution, to form a mixture; ii) optionally adjusting the pH of the protein slurry to a pH of about 2 to about 10; and iii) separating the mixture to form a protein slurry comprising soluble and insoluble proteins and an insoluble fiber fraction.

公开(公告)号：EP2573145A1

公开(公告)日：2013-03-27

申请号：EP10851760.8

申请日：2010-05-20

申请人： Riken Technos Corp. ,  BASF SE

发明人： TASAKA, Michihisa ,  KANNO, Hiroyasu

IPC分类号： C09D4/06 ,  B32B27/30 ,  C09D4/00 ,  C09D5/00 ,  C09D135/02

CPC分类号： C09D4/06 ,  C08J7/045 ,  C08J2300/22 ,  C08J2467/06 ,  C08L33/00 ,  Y10T428/265 ,  Y10T428/31507 ,  Y10T428/31649 ,  Y10T428/31797 ,  Y10T428/31913 ,  Y10T428/31928

摘要： A hard coat paint according to the present invention contains (a) vinyl ester resin or unsaturated polyester resin by 10 to 30 mass%, (b) vinyl monomer and/or (meth)acrylate monomer by 50 to 75 mass%, (c) monomer having a cyclic structure and at least one ethylenically unsaturated group in a molecule by 3 to 20 mass%, (d) a modifying agent by 0 to 10 mass% (provided that the total of the components (a) to (d) is 100 mass%) and (e) at least one radical polymerization initiator selected from a group of organic peroxides, UV reaction initiators and electron beam reaction initiators by 0.1 to 15 parts by mass relative to the total of 100 parts by mass of the components (a) to (d).

摘要翻译： 根据本发明的硬涂料包含（a）10至30质量％的乙烯基酯树脂或不饱和聚酯树脂，（b）50至75质量％的乙烯基单体和/或（甲基）丙烯酸酯单体，（c） 分子中具有环状结构和至少一个烯键式不饱和基团的单体3〜20质量％，（d）0〜10质量％的改性剂（前提条件是（a）〜（d）成分为 100质量％）和（e）选自有机过氧化物，UV反应引发剂和电子束反应引发剂的至少一种自由基聚合引发剂相对于总计100质量份的组分为0.1〜15质量份（ a）至（d）。

公开(公告)号：EP2558123A2

公开(公告)日：2013-02-20

申请号：EP11769425.7

申请日：2011-04-12

申请人： Immunovative Therapies, Ltd.

发明人： HAR-NOY, Michael

IPC分类号： A61K39/395 ,  A61K39/00 ,  C07K16/00 ,  C12N5/09 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/217 ,  A61K39/39 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/57 ,  C12N5/0637 ,  C12N2502/1114 ,  A61K2300/00

摘要： The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.

公开(公告)号：EP2434890A1

公开(公告)日：2012-04-04

申请号：EP10781180.4

申请日：2010-05-27

申请人： Tetralogic Pharmaceuticals Corp.

发明人： CONDON, Stephen, M. ,  DENG, Yijun ,  ALEXANDER, Matthew, D. ,  LAPORTE, Matthew, G.

IPC分类号： A01N43/36 ,  A61K31/40

CPC分类号： A61K31/40 ,  C07D487/04 ,  C07D519/00

摘要： The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.

公开(公告)号：EP2434889A1

公开(公告)日：2012-04-04

申请号：EP10781080.6

申请日：2010-05-25

申请人： Tetralogic Pharmaceuticals Corp.

发明人： CONDON, Stephen, M. ,  DENG, Yijun ,  LAPORTE, Matthew, G.

IPC分类号： A01N43/36 ,  A61K31/40

CPC分类号： C07D487/04 ,  C07D519/00

摘要： The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.

摘要翻译： 本发明描述了化合物，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。

公开(公告)号：EP2328555A2

公开(公告)日：2011-06-08

申请号：EP09785003.6

申请日：2009-08-24

申请人： Slotervaart Participaties BV ,  Stichting Het Nederlands Kanker Instituut

发明人： BEIJNEN, Jacob, Hendrik ,  SCHELLENS, Johannes, Henricus, Matthias ,  MOES, Johannes ,  NUIJEN, Bastiaan

IPC分类号： A61K9/14 ,  A61K9/19 ,  A61K9/48 ,  A61K31/337 ,  A61K31/426 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K9/19 ,  A61K9/141 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/4858 ,  A61K9/4866

摘要： Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant, wherein the substantially amorphous taxane is prepared by a solvent evaporation method and, in particular, spray drying. Methods of preparation of the composition and uses of the composition are also included.

公开(公告)号：EP2298350A2

公开(公告)日：2011-03-23

申请号：EP10184726.7

申请日：1997-07-28

申请人： Perrine, Susan P. ,  Faller, Douglas V. ,  White, Brian F.

发明人： Perrine, Susan P. ,  Faller, Douglas V. ,  White, Brian F.

IPC分类号： A61K45/06 ,  A61K31/52 ,  A61K31/195 ,  A61K31/70 ,  A61K31/19

CPC分类号： A61K31/19 ,  A61K31/195 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to novel compositions and to novel methods for the administration of compositions to a patient or to cells in vitro for the treatment of human disorders. In one embodiment, compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo . These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. In another embodiment, compositions contain an inducing agent and an anti-viral agent. The inducing agent induces the expression of a cellular or viral product, such as viral thymidine kinase, increasing the sensitivity of proliferating cells to the anti-viral agent. Typical anti-viral agents include nucleoside analogs such as ganciclovir that inhibit viral replication. Methods involve administration of therapeutically effective amounts of the inducing agent with the anti-viral agent to destroy virus-infected cells. Viral infections that can be treated include infections by herpes viruses such as Kaposi's-associated herpes virus and Epstein-Barr virus, HIV infections and HTLV infections. These compositions and methods are particularly effective against episomal and latent infections in proliferating cells. The invention also relates to novel methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation.

摘要翻译： 本发明涉及新颖的组合物和方法，以用于新颖的组合物到患者或在体外对人类疾病的治疗中的细胞的施用。 在一个，实施例的组合物含有化学的化合物确实刺激胎儿血红蛋白的表达和/或刺激红血细胞，白血细胞和血小板的患者增殖和体外用于体内造血重建。 这些方法是治疗或预防贫血，镰状细胞病，地中海贫血等血液疾病相关的症状。 在另一个实施方式的组合物含有在诱导剂和抗病毒剂的。 诱导剂诱导细胞或病毒产品，颜色的表达：如病毒胸苷激酶，增加增殖的细胞的抗病毒剂的灵敏度。 典型的抗病毒剂包括核苷类似物：如更昔洛韦没有抑制病毒复制。 方法涉及与抗病毒剂破坏病毒感染细胞的诱导剂的治疗有效量的管理。 病毒感染可以治疗并包括由疱疹病毒感染：如卡波西相关疱疹病毒和EB病毒，HIV感染和HTLV感染。 这些组合物和方法是针对游离的和在增殖细胞中潜伏感染特别有效。 因此，本发明涉及用于组合物的脉冲式给药的新颖的方法给患者，用于治疗和预防细胞增殖性病症，包括缺陷：如血细胞减少症和恶性肿瘤：如病毒诱导的肿瘤，其它形式的瘤形成和细胞扩增造血移植 ，

公开(公告)号：EP2275178A2

公开(公告)日：2011-01-19

申请号：EP10184691.3

申请日：2009-02-10

申请人： Nike International Ltd

发明人： Lukasiewicz, Robert Jr. ,  Boyd, Robert

IPC分类号： A63B53/04

CPC分类号： A63B53/0466 ,  A63B60/02 ,  A63B60/54 ,  A63B2053/0433 ,  A63B2053/0437 ,  A63B2053/0491 ,  A63B2209/00

摘要： Wood-type golf club heads include: (a) a club head body member defining an interior chamber; (b) a weight system engaged with a rear perimeter portion of the club head body member; and (c) a connection system connecting the weight system with the club head body (e.g., with the rear of the ball striking face portion). The club heads further may include one or more damping members in the interior chamber to alter the sound and/or otherwise attenuate a vibrational response of the club head. The damping members may extend between the ball striking face and the weight system, and optionally may engage the connection system. The damping member(s) may constitute a foam material compressed within the interior chamber of the club head. Methods of making such golf club head structures also are described.

摘要翻译： 木杆型高尔夫球杆头包括：（a）球杆头本体构件，限定出内部腔室; （B）与球杆头本体构件的后周边部分接合的配重系统; 和（c）的连接系统与球杆头主体连接的配重系统（例如，与击球面部分的后）。 球杆头可以进一步包括在内部腔室的一个或多个阻尼构件以改变声音和/或以其他方式衰减球杆头的振动响应。 阻尼部件可在击球面和配重系统之间延伸，并且任选地可接合的连接系统，该阻尼构件（一个或多个）可以构成球杆头的内部腔室中被压缩的泡沫材料。 因此，制作调查的高尔夫球杆头结构的方法描述。